Septerna, Inc. (NASDAQ:SEPN – Get Free Report)’s stock price rose 5.3% during trading on Tuesday . The stock traded as high as $36.33 and last traded at $36.6950. Approximately 21,596 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 313,273 shares. The stock had previously closed at $34.85.
Analyst Ratings Changes
SEPN has been the subject of a number of recent analyst reports. Wall Street Zen downgraded shares of Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 price objective on shares of Septerna in a research report on Tuesday, March 10th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Septerna in a research note on Wednesday, May 13th. Truist Financial upped their target price on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Septerna presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.78.
Get Our Latest Stock Report on Septerna
Septerna Stock Up 5.8%
Septerna (NASDAQ:SEPN – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The company had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, analysts predict that Septerna, Inc. will post -1.57 earnings per share for the current fiscal year.
Insider Activity at Septerna
In other Septerna news, insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88. Following the sale, the insider owned 793 shares of the company’s stock, valued at approximately $23,837.58. The trade was a 93.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at $4,240,247.06. This trade represents a 2.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 27,983 shares of company stock valued at $842,957. 5.80% of the stock is owned by insiders.
Institutional Investors Weigh In On Septerna
Hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its stake in shares of Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after purchasing an additional 1,260,409 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Septerna in the first quarter valued at approximately $21,334,000. First Light Asset Management LLC bought a new position in Septerna in the 4th quarter valued at approximately $17,308,000. Primecap Management Co. CA bought a new position in Septerna in the 4th quarter valued at approximately $15,225,000. Finally, Perceptive Advisors LLC acquired a new stake in Septerna during the 2nd quarter worth approximately $5,723,000.
Septerna Company Profile
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Read More
- Five stocks we like better than Septerna
- How Does D-Wave’s New Simulator Change the Quantum Computing Landscape?
- Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock
- The Biotech Sector Looks Ready for a Multi-Year Breakout—Here’s What to Watch.
- How Intel Is Packaging the Future of American Chips
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
